根据最新披露的条款，若德纳维制药（Dynavax）与赛诺菲（Sanofi）的合作协议因特定情形提前终止，赛诺菲需向德纳维支付高达1.168亿美元的反向终止费用。这一条款为合作关系的稳定性提供了重要保障。
该反向解约金机制旨在保护德纳维的核心利益，确保其在潜在合作变动中获得实质性补偿。双方协议的详细情形说明，仅当满足预设条件时，此项费用才会被触发。
根据最新披露的条款，若德纳维制药（Dynavax）与赛诺菲（Sanofi）的合作协议因特定情形提前终止，赛诺菲需向德纳维支付高达1.168亿美元的反向终止费用。这一条款为合作关系的稳定性提供了重要保障。
该反向解约金机制旨在保护德纳维的核心利益，确保其在潜在合作变动中获得实质性补偿。双方协议的详细情形说明，仅当满足预设条件时，此项费用才会被触发。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.